What advice do you have for the management of nail toxicity associated with pemigatinib and other FGFR inhibitors?

Pan-FGFR inhibitors as a class can cause significant dermatologic toxic effects (including alopecia, dry skin, nail changes, and stomatitis) anywhere in the range of 20% to 45%, depending on the specific agents (Lacouture et al., PMID 33021006, Bétrian et al., PMID 28538953).

Lacouture and colleagues...